| Title |
A Double-Blinded, Randomized, Placebo-Controlled Trial to Evaluate Efficacy, Safety, and Tolerability of Single Doses of Tirasemtiv in Patients with Acetylcholine Receptor-Binding Antibody-Positive Myasthenia Gravis
|
|---|---|
| Published in |
Neurotherapeutics, March 2015
|
| DOI | 10.1007/s13311-015-0345-y |
| Pubmed ID | |
| Authors |
Donald B. Sanders, Jeffrey Rosenfeld, Mazen M. Dimachkie, Lisa Meng, Fady I. Malik, for the Tirasemtiv in Myasthenia Gravis Study Group |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 63 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Unknown | 62 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 10 | 16% |
| Researcher | 7 | 11% |
| Student > Bachelor | 7 | 11% |
| Student > Master | 5 | 8% |
| Other | 4 | 6% |
| Other | 15 | 24% |
| Unknown | 15 | 24% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 23 | 37% |
| Neuroscience | 8 | 13% |
| Agricultural and Biological Sciences | 4 | 6% |
| Unspecified | 2 | 3% |
| Nursing and Health Professions | 2 | 3% |
| Other | 8 | 13% |
| Unknown | 16 | 25% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 August 2022.
All research outputs
#6,443,044
of 25,373,627 outputs
Outputs from Neurotherapeutics
#647
of 1,308 outputs
Outputs of similar age
#68,485
of 273,820 outputs
Outputs of similar age from Neurotherapeutics
#9
of 21 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one has received more attention than most of these and is in the 74th percentile.
So far Altmetric has tracked 1,308 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 18.2. This one has gotten more attention than average, scoring higher than 50% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 273,820 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.
We're also able to compare this research output to 21 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 57% of its contemporaries.